Welcome to Zyduscadila.com

Zydus Cadila is a global healthcare provider and one of the top five pharma companies in India. The company was founded by Late Mr. Ramanbhai B. Patel in 1952 and went on to become the second largest pharma company in the early 1990’s.
In 1995, the group restructured its operations and now operates as Cadila Healthcare Ltd., under the aegis of the Zydus group. The company spearheaded by Mr. Pankaj R. Patel, Chairman and Managing Director posted a turnover of over Rs. 2900 crores in 2008-09.
The group has been listed as one of the ‘Best Under a Billion’ company from amongst 200 companies in Asia by Forbes.
Proven expertise in manufacturing and marketing different dosage forms such as solid dosage forms, injectables, metered dose inhalers, dry powder inhalers, transdermal patches, suppositories and oncology formulations.
Wide therapy coverage through three multi-therapy divisions and eleven speciality divisions. The divisions are spearheaded by some of the stalwarts in the field of pharma marketing.
A dedicated field force of 3300 reaches out to super specialists, specialists, surgeons, physicians and the rural markets.
The group has a strong presence in the cardiovascular, gastrointestinal, women’s healthcare segments, respiratory, pain management, CNS, anti-infectives, oncology, neurosciences, dermatology and nephrology segments.
Leading the way through new product introductions, the group was the first to launch Nucoxia (Etoricoxib), Nupatch (Diclofenac Patch), Pantodac (Pantoprazole), Mifegest (Mifepristone), Penegra (Sildenafil Citrate), Providac Techsules, Betaferon, Fludara, Slimona (Rimonabant) and Novolizer in India.
The group has several brands that feature amongst the top 300 pharmaceutical brands in India.
The group has a globally compliant manufacturing infrastructure comprising eight state-of-the-art facilities which support product launches not just in India but also in the regulated markets of U.S., Europe and Latin America.
Three of the group’s facilities including the formulation manufacturing plant at Moraiya, and API plants at Ankleshwar and Dabhasa near Vadodara are approved by the USFDA.
More than 900 professionals spearhead the group’s research programme.
Over 350 scientists are working on new molecular entity research at the Zydus Research Centre. The group has six INDs in various stages of clinical trials and two more INDs are in pre-clinical evaluation.
Zydus Cadila is a partner of choice for several global pharma majors such as Boehringer Ingelheim, Bayer Schering Pharma, Madaus AG, Nycomed, Hospira, Bio Sidus of Argentina, Mallinckrodt of USA, to name a few.
One of the most reputed pharma companies globally, Zydus Cadila aims to be a leading global healthcare provider with a robust product pipeline and sales of over $1 billion by 2010. It plans to achieve sales of over $3 billion by 2015 and be a global research-driven company by 2020.